DISCO–Amgen License Deal Advances Surfaceome Cancer Therapies
COLOGNE, Germany – January 7, 2026 — DISCO Pharmaceuticals has entered into an exclusive global license agreement with Amgen...
Licensing Agreement
Advertisement
Emmaus Licenses Endari® in North America to NeoImmuneTech
Torrance, California | December 30, 2025 — Emmaus Life Sciences, Inc. has announced a strategic licensing and exclusive distribution...
MEDIPOST Secures Japan Commercial Deal for CARTISTEM® Therapy
Seoul, South Korea, December 19, 2025 — MEDIPOST Co., Ltd., a fully integrated cell therapy biotechnology company, has entered...
Gobivaz Biosimilar Earns EEA Approval, Expanding Access to Anti-TNF Therapy
Reykjavik & London, November 2025 Alvotech and Advanz Pharma have received marketing approval across the European Economic Area (EEA)...
PetVivo & Digital Landia Reveal AI Framework Transforming Veterinary Care
Dateline – November 17 2025 | Minneapolis & Miami PetVivo Holdings, Inc. announced that its exclusive AI-technology partner, Digital...
Advertisements
VectorY and ShapeTX Partner to Advance AAV5-Based CNS Therapies
AMSTERDAM, BOSTON, and SEATTLE – Sept. 18, 2025 (cGxP.wire) – VectorY Therapeutics, a biotechnology company pioneering vectorized antibody therapies...
Monte Rosa and Novartis Expand Degrader Alliance in Immunology
BOSTON, Mass., September 15, 2025 – Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company pioneering molecular glue...
Advertisement
